Results 161 to 170 of about 20,950 (257)

Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy

open access: yesDermatology Practical & Conceptual
Introduction: Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis. Objective: We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two ...
Federico Pirro   +21 more
doaj   +1 more source

Periodontitis and rheumatoid arthritis—Global efforts to untangle two complex diseases

open access: yesPeriodontology 2000, EarlyView.
Abstract Understanding the impact of oral health on rheumatoid arthritis (RA) will inform how best to manage patients with both periodontitis and RA. This review seeks to provide an update on interventional and mechanistic investigations, including a brief summary of European Research programs investigating the link between periodontitis and RA. Recent
Isabel Lopez‐Oliva   +2 more
wiley   +1 more source

Interplay between COVID-19 and Secukinumab treatment in Spondylarthritis patients during the omicron surge: a retrospective cohort study

open access: yesAutoimmunity
The objective of this retrospective cohort study was to assess the relationship between Corona Disease 2019 (COVID-19) and Secukinumab treatment in patients with Spondylarthritis (SpA) in China during the omicron surge. Researchers retrieved 1018 medical
Tong Wu   +13 more
doaj   +1 more source

Secukinumabbal szerzett klinikai tapasztalataink krónikus plakkos psoriasisban szenvedő betegek terápiájában [PDF]

open access: yes, 2018
L
Gáspár, Krisztián   +3 more
core  

Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 2, February 2026.
Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo   +11 more
wiley   +1 more source

Engagement and retention with remote monitoring in psoriasis: Findings from the mySkin study

open access: yes
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Weiyu Ye   +22 more
wiley   +1 more source

Pathogenesis of Vitiligo: Integrating Immune and Non‐Immune Cell Crosstalk

open access: yesThe Journal of Dermatology, Volume 53, Issue 2, Page 188-199, February 2026.
ABSTRACT Vitiligo is an acquired autoimmune disease characterized by depigmented macules resulting from melanocyte loss. It is a complex multifactorial disorder in which genetic predisposition is combined with environmental factors; however, its detailed etiology remains unclear.
Shintaro Inoue
wiley   +1 more source

Sex Differences in Response and Persistence to Biologic Therapy in Psoriatic Arthritis: A 52‐Week Analysis With Extended Long‐Term Outcomes

open access: yesThe Journal of Dermatology, Volume 53, Issue 2, Page 219-230, February 2026.
ABSTRACT Psoriatic arthritis (PsA) is a chronic immune‐mediated disease with heterogeneous joint and skin manifestations. Although biologic therapies targeting TNFα, IL‐17, and IL‐23 have transformed PsA management, sex‐specific differences in efficacy and treatment persistence remain underexplored.
Keita Ohyachi   +5 more
wiley   +1 more source

Real‐World Safety Profile of Spesolimab in Generalized Pustular Psoriasis: Insights From Japan as Part of a Multinational Expanded Access Program (EAP)

open access: yesThe Journal of Dermatology, Volume 53, Issue 2, Page 351-356, February 2026.
ABSTRACT Generalized pustular psoriasis (GPP) is a heterogeneous, systemic neutrophilic inflammatory disease, characterized by chronic symptoms and recurrent flares, which can be potentially life‐threatening. Spesolimab, an interleukin‐36 receptor antagonist, has been approved to treat GPP flares in many countries including Japan.
Akimichi Morita   +12 more
wiley   +1 more source

S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situations

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 2, Page 270-282, February 2026.
Summary The present Part 2 of the updated German S3 guideline on the treatment of psoriasis vulgaris provides recommendations for therapy selection in special clinical situations and in the presence of comorbidities. A major focus of this update is the chapter on screening for tuberculosis as well as therapy selection and management in latent ...
Alexander Nast   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy